Recruiting
Phase 1

Quinidine Sulfate

Sponsor:

Trevi Therapeutics

Code:

NCT07946575

Conditions

Healthy Participants

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Interventions

NAL ER

Quinidine Sulfate

Study Details

Brief summary:

The primary purpose of this study is to evaluate the effect of quinidine sulfate on the pharmacokinetics (PK) of NAL ER in healthy participants.

Conditions

Healthy Participants

Study ID

NCT07946575

Start date

Nov 3, 2026

Status verified date

Nov, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Nov 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Key Inclusion Criteria:

  • Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kilogram per meter square (kg/m\^2) at screening.
  • Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), as deemed by the principal investigator (PI) or designee.

Exclusion Criteria:

  • History of any diagnosed moderate or severe substance use disorder, other than tobacco use disorder, or a history of or current regular excessive consumption of alcohol.
  • Positive urine drug or alcohol results.
  • Smoker who has smoked or used nicotine containing products within the last 3 months.
  • Clinically significant hypokalemia or hypomagnesemia at the screening visit.
  • History of prolonged QT syndrome.
  • Abnormal liver tests at screening.
  • Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
  • Abnormal estimated glomerular filtration rate (eGFR).

Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: NAL ER and Quinidine

Participants will receive NAL ER followed by NAL ER co-administered with quinidine.

Interventions

NAL ER

Oral tablets

Quinidine Sulfate

Oral tablets

Primary outcome measure

  • Maximum Plasma Concentration (Cmax) of NAL ER [ Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9 ]
  • Time to Reach Maximum Observed Concentration (Tmax) of NAL ER [ Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9 ]
  • Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUC0-Tlast) of NAL ER [ Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9 ]
  • Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of NAL ER [ Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9 ]
  • Apparent Terminal Rate Constant (λz) of NAL ER [ Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9 ]
  • Apparent Terminal Half-Life (t1/2) of NAL ER [ Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9 ]

Central Contacts and Locations

Central contacts

Locations

Clinical Pharmacology of Miami, LLC

Recruiting

Miami, Florida, United States, 33172

More Information

Sponsor

Trevi Therapeutics

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Trevi Therapeutics on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.